Introduction: The World Health Organization (WHO) has recently declared the outbreak
and spread of the new strain of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS--
CoV-2) a global pandemic. In this regard, a lot of scientific investigations and clinical trials on
some existing antiviral and antibiotic drugs have been ongoing to combat this menace.
Methods: In the past, conventional drug therapy has shown irregular drug distribution, poor solubility,
and low permeability to target cells, organs, and tissues. However, Chloroquine, Hydroxychloroquine
Remdesivir, Lopinavir/Ritonavir, etc. have attracted several investigations in monotherapeutic
approaches and a combination of therapy have shown promising effects in reducing viral
loading in some SARS-CoV-2 infected patients. Nevertheless, the advent of nanomedicine has
triggered serious attention on drug-loaded nanoparticle as nanocarriers to deliver bioactive drug
molecules to target organs with increased circulation and controlled release. Therefore, the application
of nanoparticles as nanocarriers for the controlled release of antiviral drugs would improve the
ease of drug administration and care of patients admitted at various health care facilities worldwide.
Conclusion: Owing to their small sizes, biocompatibility, and high encapsulation properties, nanoparticles
can be utilized as potential nanocarrier of antiviral drugs for the SARS-CoV-2 management
at a reduced cost with minimal side effect in the body system. In addition, some noticeable
concerns on the ongoing management of SARS-CoV-2 pandemic in developing nations have been
presented for concerted attention.